Aclarubicin - CAS 57576-44-0
Catalog number: 57576-44-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. It intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. It is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. It has potent antineoplastic activity. It is used in the treatment of cancer. It can induce histone eviction from chromatin upon intercalation. It has been listed.
Publictions citing BOC Sciences Products
  • >> More
Yellow crystalline powder
11-Dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-met;1-naphthacenecarboxylicacid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6;(1R,2R,4S)-methyl 4-(((2R,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)
Soluble in DMSO (25mg/ml) or dimethyl formamide (25mg/ml).
Aclarubicin has potent antineoplastic activity. It is used in the treatment of cancer. It can induce histone eviction from chromatin upon intercalation.
Quality Standard:
In-house standard
Kilograms to Tons
Boiling Point:
897.7±65.0 °C | Condition: Press: 760 Torr
Melting Point:
151-153 °C (decomp)
1.42±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Aclarubicin has been listed.
1.Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase.
Komiyama T, Kikuchi T, Sugiura Y. Biochem Pharmacol. 1982 Nov 15;31(22):3651-6.
The generation of hydroxyl free radicals in the system consisting of purified NADPH-cytochrome P-450 reductase and anticancer quinone drugs, such as carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, has been confirmed by two methods. In the spin trapping study, using N-tert-butyl-alpha-phenylnitrone as the spin trapping agent, four drugs generated hydroxyl radical-trapped signals, and the formation of the spin adduct was dependent on time and the enzyme concentration. Among the four drugs, the generation time of signal was in the order of carbazilquinone, aclacinomycin A, adriamycin and mitomycin C, but the magnitude of signal intensity was different. In both aclacinomycin A and adriamycin, the signal disappeared in a few minutes. Catalase completely inhibited the formation of the spin adduct, while superoxide dismutase did not significantly inhibit, but effected in some manner. The generation of hydroxyl radical was also confirmed by the ethylene production from methional.
2.Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Fujimoto S, Ogawa M. Cancer Chemother Pharmacol. 1982;8(2):157-62.
1,4-Dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino] ethyl)amino))-9,10-anthracenedione dihydrochloride (mitoxantrone) was tested for antitumor activity against experimental tumors in mice and the results were compared with those of seven antitumor antibiotics: adriamycin (ADM), daunomycin (DM), aclarubicin, mitomycin C (MNC), bleomycin, neocarzinostatin, and chromomycin A3. The drugs were given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produced a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. The curative effect was not observed with any of the other antibiotics. In the case of IV implanted L1210 leukemia, there was an increase in lifespan (ILS) by more than 100% in the mice following IV treatment with mitoxantrone or DM. In IP implanted P388 leukemia, the curative effect was elicited by IP treatment with mitoxantrone or MMC.
3.Interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C, with NADPH-cytochrome P-450 reductase, xanthine oxidase and oxygen.
Komiyama T, Kikuchi T, Sugiura Y. J Pharmacobiodyn. 1986 Aug;9(8):651-64.
The properties of the interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C with nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P-450 reductase and xanthine oxidase under anaerobic and aerobic conditions were studied. Km values of NADPH-cytochrome P-450 reductase for these drugs were in the range of 40-227 microM, and that of deflavo xanthine oxidase in the range of 39-over 200 microM. Under anaerobic conditions, when xanthine was used as an electron donor, deflavo xanthine oxidase catalyzed the reductive glycosidic cleavage reaction of anthracyclines and nicotinamide adenine dinucleotide was ineffective as an electron donor. In the electron spin resonance study, the formation of the semiquinone or free radical state of the quinone drugs in both enzyme systems were evidenced. A weak and symmetric signal was obtained from aclacinomycin A, and a symmetric signal from adriamycin was changed into an asymmetric and strong.
4.Thermodynamics of the anthracycline-nuclei interactions in drug-resistant and drug-sensitive K562 cells.
Tarasiuk J1, Garnier-Suillerot A. Biochem Pharmacol. 1992 Jun 23;43(12):2575-80.
Fluorescence emission spectra from anthracycline-treated cells suspended in buffer have been used to measure the uptake of three anthracycline derivatives: Adriamycin (ADR), 4'-o-tetrahydropyranyl-Adriamycin (THP-ADR) and aclacinomycin (ACM) in drug-sensitive and drug-resistant K562 cells. The concentration of drug bound to the nucleus and free in the cytoplasm, at steady state, as well as the concentration of drug bound to the nucleus at equilibrium state have been determined at temperatures ranging from 6 degrees to 40 degrees. The enthalpies for the binding of ADR, THP-ADR and ACM to nuclei equal -35 +/- 3, -35 +/- 3 and -30 +/- 3 kJ/mol, respectively. These values compare with the enthalpies of binding of these drugs to naked DNA.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Topoisomerase Products

CAS 175519-16-1 Voreloxin Hydrochloride

Voreloxin Hydrochloride
(CAS: 175519-16-1)

Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result...

CAS 136572-09-3 Irinotecan Hydrochloride Trihydrate

Irinotecan Hydrochloride Trihydrate
(CAS: 136572-09-3)

The hydrochloride salt of Irinotecan. Irinotecan is a prodrug that can be activated to 7-ethyl-10-hydroxy-camptothecin (SN-38) by the carboxylesterase-convertin...

CAS 169869-90-3 Exatecan mesylate

Exatecan mesylate
(CAS: 169869-90-3)

Exatecan mesylate is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity...

CAS 1562066-98-1 Banoxantrone D12 dihydrochloride

Banoxantrone D12 dihydrochloride
(CAS: 1562066-98-1)

The deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a potent topoisomerase II inhibitor.

Alatrofloxacin Mesylate
(CAS: 157605-25-9)

The mesylate salt form of alatrofloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed to be...

Elomotecan HCl salt
(CAS: 220997-99-9)

Elomotecan, also referred to BN 80927 and R 1559, characterized by a stable seven-membered beta-hydroxylactone ring, is a DNA topoisomerase inhibitor. In vivo e...

CAS 1562067-05-3 Banoxantrone D12

Banoxantrone D12
(CAS: 1562067-05-3)

The deuterium labeled banoxantrone which was rationally designed to have anti-tumor activity following bioreduction by tissue cytochrome P450 to AQ4, an active ...

CAS 211100-13-9 Sabarubicin

(CAS: 211100-13-9)

Sabarubicina, a disaccharide analogue of doxorubicin, is an antineoplastic agent which can intercalate into the DNA of tumor cells and interact with topoisomera...

CAS 56420-45-2 Epirubicin

(CAS: 56420-45-2)

Epirubicin, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. It is clinically active against a broad...

CAS 161967-81-3 Grepafloxacin Hydrochloride

Grepafloxacin Hydrochloride
(CAS: 161967-81-3)

The hydrochloride salt form of Grepafloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor and was once studied as a...

CAS 867063-97-6 Atiratecan

(CAS: 867063-97-6)

Atiratecan is a topoisomerase inhibitor. It has potential anticancer activity.

CAS 175414-77-4 Voreloxin

(CAS: 175414-77-4)

Voreloxin(SNS-595; AG 7352) is a small molecule and a naphthyridine analogue with antineoplastic activity; inhibitor of Topo II.

CAS 169869-90-3 Exatecan Mesylate

Exatecan Mesylate
(CAS: 169869-90-3)

Exatecan Mesylate (DX-8951) is a totally synthetic analogue of the topoisomerase I-inhibitor camptothecin, which was synthesised to impart increased aqueous sol...

CAS 162706-37-8 Elinafide

(CAS: 162706-37-8)

Elinafide, an isoquinoline derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in anticancer studies.

CAS 252979-56-9 Banoxantrone dihydrochloride

Banoxantrone dihydrochloride
(CAS: 252979-56-9)

Banoxantrone dihydrochloride, a bioreductive prodrug, can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor, and ex...

CAS 123948-87-8 Topotecan

(CAS: 123948-87-8)

Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions. ...

CAS 56390-09-1 Epirubicin Hydrochloride

Epirubicin Hydrochloride
(CAS: 56390-09-1)

Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase.

(CAS: 522650-83-5)

SW044248 is a potent and selective Topoisomerase I inhibitor. SW044248 killed approximately 15% of a panel of 74 NSCLC cell lines and was nontoxic to immortaliz...

CAS 446-72-0 Genistein

(CAS: 446-72-0)

Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by ...

CAS 86639-52-3 SN-38

(CAS: 86639-52-3)

SN-38 is the active metabolite of irinotecan. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN...

Chemical Structure

CAS 57576-44-0 Aclarubicin

Quick Inquiry

Verification code

Featured Items